Clinical Trials

Clinical Trials for MTG6

Filter list of Clinical Trials

TopicTrial name of investigational drugClinical Trial ID(s)StatusOrphaCodeLink
Bardet Biedl Syndrome (BBS) Alström Syndrome (AS)Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity Phase 3
  • NCT03746522
  • concluded
  • OPRHA240371
  • OPRHA64
  • ORPHA110
Genetic ObesitySetmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
  • NCT03651765
  • ongoing
  • recruiting
  • OPRHA240371
  • OPRHA64
  • ORPHA110
Diabetes InsipidusCARGOx - Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study (CARGOx)
  • NCT03572166
  • ongoing
  • recruiting
  • ORPHA178029
Genetic ObesitySetmelanotide for the Treatment of LEPR Deficiency Obesity
  • NCT03287960
  • concluded
  • ORPHA179494
ProlactinomaPROLACT A Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia
  • NCT04107480
  • ongoing
  • recruiting
  • ORPHA2965
Transition,paediatric chronic endocrine disordersGrowing up With the Young Endocrine Support System (YESS!) (YESS)
  • NCT04252001
  • ongoing
  • ORPHA418
  • ORPHA174590
  • ORPHA881
  • ORPHA95488
  • ORPHA85138
  • ORPHA754
  • ORPHA9571
  • ORPHA95494
Hypothalamic ObesityEfficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy (CRANIOEXE)
  • NCT02860923
  • concluded
  • ORPHA54595
Cushing SyndromeLOGICS: A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome (Levoketoconazole).
  • NCT03277690
  • concluded
  • ORPHA553
  • ORPHA99892
  • ORPHA99893
Cushing SyndromeAn Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
  • NCT03606408
  • ongoing
  • ORPHA553
  • ORPHA99892
  • ORPHA99893
Cushing SyndromeAn Open-Label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
  • NCT03621280
  • COR-2017-OLE
  • ongoing
  • ORPHA553
  • ORPHA99892
  • ORPHA99893
McCune- Albright SyndromeMCRN007 (D6992C00044) - An Open-Label, Non-Comparative Trial To Evaluate The Safety, Efficacy And Pharmacokinetics Of FASLODEX™ (Fulvestrant) In Girls With Progressive Precocious Puberty Associated With Mccune Albright Syndrome
  • NCT00278915
  • ongoing
  • ORPHA562
Genetic ObesitySetmelanotide for the Treatment of Early-Onset POMC Deficiency Obesity
  • NCT 02896192
  • concluded
  • ORPHA71526
Genetic ObesityLong Term Extension Trial of Setmelanotide
  • NCT 03013543
  • ongoing
  • ORPHA71526
Genetic ObesityRM-493-22 (A Phase 2, Two-Stage (Open-Label Run-in Followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled Study of Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway)
  • NCT04963231
  • concluding
  • ORPHA71529
Growth Hormone DeficiencyInvestigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
  • NCT02616562
  • ongoing
  • recruiting
  • ORPHA95488
Growth Hormone DeficiencySafety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
  • NCT03874013
  • completed
  • ORPHA95488
Growth Hormone DeficiencyA Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency (foresiGHt)
  • NCT04615273 (TCH-306)
  • ongoing
  • recruiting
  • ORPHA95488
Growth Hormone DeficiencyA Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA)
  • MOD-4023 (2) - OLE
  • completed
  • ORPHA95488
Growth Hormone DeficiencyA phase 3 trial evaluating the effect of long acting GH (MOD-4023) in patients with GHD. CP-4-005
  • NCT01909479
  • completed
  • ORPHA95488
Growth Hormone DeficiencyA Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
  • NCT02781727
  • completed
  • ORPHA95488
Growth Hormone DeficiencySafety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
  • NCT02968004
  • ongoing
  • ORPHA95488
Growth Hormone DeficiencyTransCon hGH 301-CT Ext (1) Enlighten (weekly GH/Transcon
  • NCT03344458
  • ongoing
  • ORPHA95488
Growth Hormone DeficiencyA trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency (REAL 4)
  • NCT03811535
  • ongoing
  • ORPHA95488
Growth Hormone DeficiencyA PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROPIN (REGISTERED)) INJECTIONS IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
  • NCT03831880
  • completed
  • ORPHA95488
Growth Hormone DeficiencyRegistre belge des enfants traités par hormone de croissance BELGROW
  • BELGROW
  • ongoing
  • ORPHA95488
  • ORPHA314795
  • ORPHA364526
Cushing DiseaseEfficacy and Safety Evaluation of Osilodrostat in Cushing's Disease (LINC-4)
  • NCT02697734
  • completed
  • ORPHA96253
Cushing DiseaseA proof of concept, open-label, forced titration, multi-center study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 followed by a 12-week treatment period in patients with Cushing’s disease
  • NCT01331239
  • completed
  • ORPHA96253
Cushing DiseasePhase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
  • NCT02180217
  • completed
  • ORPHA96253
Cushing DiseaseA phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease
  • NCT03708900
  • ongoing
  • recruiting
  • ORPHA96253
AcromegalyComparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly (MPOWERED).
  • NCT02685709
  • completed
  • ORPHA963
AcromegalyEfficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
  • NCT03252353
  • ongoing
  • ORPHA963
AcromegalyAn open label exploratory study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens (ACROBAT EDGE)
  • NCT03789656
  • concluded
  • ORPHA963
AcromegalyA double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide lar or lanreotide depot (ACROBAT EVOLVE)
  • NCT03792555
  • concluded
  • ORPHA963
AcromegalyA Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot(CAM2029) in patients with acromegaly.
  • NCT04076462 (HS-18-633)
  • ongoing
  • recruiting
  • ORPHA963
AcromegalyA Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
  • NCT04125836 (HS-19-647)
  • ongoing
  • recruiting
  • ORPHA963
AcromegalyEuropea Observational study in Acromegaly - Acronis Study
  • CSOM230CIC05
  • recruiting
  • ORPHA963
Cushing Disease and AcromegalyAn Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
  • NCT01794793
  • ongoing
  • ORPHA963
Cushing SyndromeGRACE-2
  • NCT03604198
  • CORT125134-452
  • 2018-001616-30
  • ongoing
  • ORPHA99892
  • ORPHA96253
  • ORPHA99889
Cushing SyndromeGlucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
  • NCT03697109
  • CORT125134-455
  • NL68116.078.18
  • ongoing
  • ORPHA99892
  • ORPHA96253
  • ORPHA99889
TopicTrial name of investigational drugClinical Trial ID(s)StatusOrphaCodeLink
Last update: May 19, 2022 on 11:02

An overview of all Clinical Trials can be found here.